Tag: Thromboembolic events

Intravitreal anti-VEGF injections have a low incidence of complications like endophthalmitis, typically ranging from 0.019% to 1.6% in clinical trials. However, understanding the specific contraindications for anti-VEGF therapy is crucial for patient safety and preventing potential adverse events, particularly serious ocular infections, inflammation, and systemic issues.

Although considered a low risk, clinical trial data showed that patients receiving Vabysmo have experienced serious, sometimes fatal, arterial thromboembolic events (ATEs), such as heart attacks or strokes. This raises the important question: Can vabysmo cause heart problems? The potential for cardiovascular side effects is a critical consideration for patients and healthcare providers.

According to the U.S. Food and Drug Administration (FDA) label, the most common adverse reactions reported in clinical trials for RiaSTAP were fever and headache. It is crucial for patients and caregivers to be aware of **what are the side effects of RiaSTAP?** to ensure proper monitoring and management during treatment.